Abstract

Lecanemab and Donanemab as Therapies for Alzheimer's Disease: An Illustrated Perspective on the Data.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call